Manufacturer of Seliniso (Sivio)

Selinexor (Selinexor) is produced by Karyopharm Therapeutics Inc., a U.S. biopharmaceutical company. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts, USA (Newton, Massachusetts). As a biopharmaceutical company focused on developing treatments for cancer and other serious diseases, Karyopharm Therapeutics Inc. is focused on developing novel anti-cancer drugs and treatments to meet patients' needs for innovative treatments.

Karyopharm Therapeutics Inc. is dedicated to the discovery and development of therapeutic drugs targeting nuclear transport and gene expression regulation. Its research focuses include selective inhibitors of nuclear export (Selective Inhibitor of Nuclear Export, SINE) and other targeted therapeutic drugs, as well as immunomodulators. The company's goal is to provide patients with more effective and safer treatment options and improve the success rate and survival rate of clinical treatment through innovative drug development and clinical trials.

Selinexor (Silvio) (Selinexor) is one of the main products of Karyopharm Therapeutics Inc., and its R&D and production teams have been working tirelessly to promote the clinical application and marketing of this drug. The launch and use of Selinisol (Silvio) marks an important breakthrough for Karyopharm Therapeutics Inc. in the field of tumor treatment and lays a solid foundation for the company's development and growth.

As a biopharmaceutical company dedicated to improving the quality of patients' lives,Karyopharm Therapeutics Inc.'s mission is to provide hope and support to those facing the challenges of cancer and other serious diseases through innovative science, technology and treatments. With the continuous advancement of science and technology and the continuous accumulation of clinical practice, Karyopharm Therapeutics Inc.We will continue to work hard to bring more treatment innovations and medical advancements to patients around the world.